Why this newly public biotech could become a force in obesity treatments
marketwatch.com/story/why-this-newly-public-biotech-could-become-a-force-in-obesity-treatments-11440ff7Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up.
This story appeared on marketwatch.com, 2025-02-25 18:42:00.